hexarelin vs tesamorelin: Frequently asked questions

Switch to a 2-on/1-off weekly cycle immediately. Continuous daily hexarelin administration downregulates GHS-R1a receptors on somatotroph cells, reducing GH secretion response by 40–60% after 8–12 weeks of uninterrupted use. Implementing a washout period (7–10 days off peptide) allows receptor resensitisation. Most protocols restore 80–90% of initial GH peak response after washout. Tesamorelin doesn't exhibit this pattern because GHRH receptors maintain sensitivity under chronic stimulation.

Eliminate hexarelin from consideration entirely. Its direct cardiotoxic effects through GHS-R1a receptors in cardiac tissue create unacceptable risk in subjects with hypertension, arrhythmias, or metabolic syndrome. Tesamorelin + ipamorelin produces no measurable cardiovascular stress at therapeutic doses. Phase III trials in HIV lipodystrophy patients (a population with elevated baseline cardiovascular risk) documented zero cardiac adverse events across 26-week treatment periods. The blend's selectivity eliminates the cardiac variable that would otherwise confound your results.

Choose hexarelin at 150–200mcg twice daily (morning and pre-sleep). The acute GH pulses will peak at 40–80 ng/mL within 30 minutes of administration, far exceeding what tesamorelin + ipamorelin produces in the same timeframe. Six weeks falls well within hexarelin's efficacy window before receptor desensitisation becomes protocol-limiting. Monitor cardiovascular parameters (heart rate, blood pressure) at baseline and weekly. Doses above 200mcg introduce measurable cardiac load even in healthy subjects.

Rotate injection sites across abdomen, thighs, and deltoids to prevent lipohypertrophy. Both hexarelin and tesamorelin are administered subcutaneously at volumes typically 0.2–0.5mL per injection. Repeated injections in the same site cause localized inflammation and adipose tissue changes. If erythema or induration persists beyond 48 hours, check reconstitution technique: injecting bacteriostatic water too forcefully creates foam and denatures peptide structure, increasing immunogenicity. Inject slowly, allowing water to run down the vial wall.

Reassess caloric intake and activity levels before assuming peptide failure. The TRIM study showed VAT reduction plateaus around week 26 in most subjects because GH-mediated lipolysis is substrate-dependent. It accelerates fat oxidation but doesn't override energy balance. If dietary intake matches expenditure, further fat loss stops regardless of GH elevation. Tesamorelin maintains its GH-stimulating effect through 52 weeks without tolerance, so continued visceral fat reduction requires sustained caloric deficit.

Switch to tesamorelin (1–2mg nightly) + ipamorelin (200–300mcg twice daily). By week 10–12, hexarelin's efficacy will have dropped 40–50%, forcing you to either escalate doses (increasing cardiovascular risk) or accept declining GH output that confounds your data. The combination blend maintains consistent IGF-1 elevation. The reliable downstream marker of GH activity. Through 24-week cycles without requiring dose adjustments. This stability matters in metabolic studies, body composition research, or any endpoint where sustained GH exposure is the independent variable.

Consider alternating protocols rather than combining peptides simultaneously. Hexarelin's CD36-mediated cardioprotective effects are most pronounced at 2mg/kg dosing 3× weekly, while tesamorelin's visceral fat targeting requires daily 2mg dosing. Running both concurrently introduces overlapping GH stimulation that complicates dose-response analysis and increases risk of IGF-1 elevation beyond physiological ranges. Sequential protocols. 12 weeks hexarelin for cardiac endpoints, followed by 26 weeks tesamorelin for metabolic endpoints. Allow clearer outcome attribution.

Use tesamorelin + ipamorelin exclusively. Hexarelin elevates cortisol by 25–40% at research doses, introducing a massive confounding variable into any study measuring HPA axis function, stress adaptation, or metabolic outcomes influenced by glucocorticoid signalling. Ipamorelin's receptor selectivity avoids cortisol and prolactin pathways entirely. This is the specific reason it was developed as a next-generation secretagogue. If your research measures cortisol, inflammation markers, or glucocorticoid-sensitive endpoints, hexarelin destroys your data quality.